Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 8/20 | 0.41 |
| ▸ | TACR1 | P25103 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665572 | 0.91 | TACR2 (0.42) | TACR2TACR1KMT2ASIGMAR1 | |
| SCHEMBL6663281 | 0.91 | TACR2 (0.42) | TACR2TACR1KMT2ASIGMAR1 | |
| Burapitant SCHEMBL1281820 | 0.89 | TACR2 (0.40) | TACR2TACR1KMT2A | |
| Burapitant SCHEMBL1281822 | 0.89 | TACR2 (0.40) | TACR2TACR1KMT2A | |
| Burapitant SCHEMBL29809744 | 0.89 | TACR2 (0.40) | TACR2TACR1KMT2A | |
| Burapitant SCHEMBL29371980 | 0.89 | TACR2 (0.40) | TACR2TACR1KMT2A | |
| SCHEMBL6663404 | 0.89 | TACR2 (0.41) | TACR2TACR1KMT2ASIGMAR1 | |
| Burapitant SCHEMBL6952686 | 0.88 | TACR2 (0.39) | TACR2TACR1KMT2A | |
| Hydrochloric Acid SCHEMBL6946688 | 0.88 | TACR2 (0.41) | TACR2TACR1KMT2ASIGMAR1 | |
| SCHEMBL6664427 | 0.84 | TACR1 (0.43) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | claimed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | claimed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | claimed |
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |